Your web browser is out of date.
For your security and improved experience online, please update your browser.
Your web browser is out of date.
Diabetes on the Net is intended for healthcare professionals
Professor Naveed Sattar
Professor of Metabolic Medicine, Institute of Cardiovascular & Medical Sciences, University of Glasgow; Honorary Consultant in Metabolic Medicine, Glasgow Royal Infirmary
Professor Martin Cowie
Professor of Cardiology, Health Services Research, Imperial College, University of London; Honorary Consultant, Royal Brompton and Harefield NHS Trust
Webcast introduction
Professor Martin Cowie
Type 2 diabetes, cardiovascular outcomes and the role of SGLT2 inhibitors
Professor Naveed Sattar
Putting the evidence into practice: does the cardiologist have an expanded role in the treatment of type 2 diabetes?
Professor Martin Cowie
Live panel discussion
Professors Martin Cowie and Naveed Sattar
Live Q&A session
Closing comments
Jardiance is the most initiated SGLT2i inhibitor in the UK1*
Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise2
Both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.2
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 3281627 (freephone)
Defined as new patients prescribed JARDIANCE, patients switched to JARDIANCE from another type 2 diabetes treatment or JARDIANCE added to another type 2 diabetes treatment
get the latest news
subscribe now
© Copyright OmniaMed Communications. All Rights Reserved
We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.